The role of M1 and M2 macrophage polarization in progression of medication-related osteonecrosis of the jaw

Pazianas M (2011) Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 103(3):232–240. https://doi.org/10.1093/jnci/djq516 Nonnenmuhlen N, Burnic A, Bartella A, Lethaus B, Gerhards F, Ristow O, Pautke C, Holzle F, Steiner T (2019) Comparison of mucosal and mucoperiosteal wound cover for the treatment of medication-related osteonecrosis of the jaw lesions: a retrospective cohort study. Clin Oral Investig 23(1):351–359. https://doi.org/10.1007/s00784-018-2443-9 Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss PJ (2017) Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin Oral Investig 21(1):127–134. https://doi.org/10.1007/s00784-016-1762-y Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F, American Association of O, Maxillofacial S (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 72(10):1938–1956. https://doi.org/10.1016/j.joms.2014.04.031 Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–1117. https://doi.org/10.1016/s0278-2391(03)00720-1 Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733–759. https://doi.org/10.1007/s00198-007-0540-8 Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209–257. https://doi.org/10.1196/annals.1402.089 Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009) Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45(2):164–172. https://doi.org/10.1016/j.oraloncology.2008.04.013 Aghaloo TL, Kang B, Sung EC, Shoff M, Ronconi M, Gotcher JE, Bezouglaia O, Dry SM, Tetradis S (2011) Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res 26(8):1871–1882. https://doi.org/10.1002/jbmr.379 Hadaya D, Soundia A, Gkouveris I, Dry SM, Aghaloo TL, Tetradis S (2019) Development of medication-related osteonecrosis of the jaw after extraction of teeth with experimental periapical disease. J Oral Maxillofac Surg 77(1):71–86. https://doi.org/10.1016/j.joms.2018.08.010 Soundia A, Hadaya D, Esfandi N, de Molon RS, Bezouglaia O, Dry SM, Pirih FQ, Aghaloo T, Tetradis S (2016) Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease. Bone 90:133–141. https://doi.org/10.1016/j.bone.2016.06.011 Khan A, Morrison A, Cheung A, Hashem W, Compston J (2016) Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int 27(3):853–859. https://doi.org/10.1007/s00198-015-3335-3 Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63(11):1567–1575. https://doi.org/10.1016/j.joms.2005.07.010 Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Sturzenbaum S, Pautke C (2012) Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40(4):303–309. https://doi.org/10.1016/j.jcms.2011.05.003 Rasmusson L, Abtahi J (2014) Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent 2014:471035–471039. https://doi.org/10.1155/2014/471035 Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M (2018) Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 69:177–187. https://doi.org/10.1016/j.ctrv.2018.06.007 Silva LF, Curra C, Munerato MS, Deantoni CC, Matsumoto MA, Cardoso CL, Curi MM (2016) Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. Oral Maxillofac Surg 20(1):9–17. https://doi.org/10.1007/s10006-015-0538-x Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta GM, Gennai S, Goia F, Miccoli M, Peluso F, Scoletta M, Solazzo L, Colella G (2012) Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. J Oral Maxillofac Surg 70(11):2501–2507. https://doi.org/10.1016/j.joms.2012.05.019 Davies LC, Jenkins SJ, Allen JE, Taylor PR (2013) Tissue-resident macrophages. Nat Immunol 14(10):986–995. https://doi.org/10.1038/ni.2705 Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6:13. https://doi.org/10.12703/P6-13 Xue Q, Yan Y, Zhang R, Xiong H (2018) Regulation of iNOS on immune cells and its role in diseases. Int J Mol Sci 19(12). https://doi.org/10.3390/ijms19123805 Murakami M, Kamimura D, Hirano T (2019) Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity 50(4):812–831. https://doi.org/10.1016/j.immuni.2019.03.027 Ariel A, Maridonneau-Parini I, Rovere-Querini P, Levine JS, Muhl H (2012) Macrophages in inflammation and its resolution. Front Immunol 3:324. https://doi.org/10.3389/fimmu.2012.00324 Tsuchiya K, Suzuki Y, Yoshimura K, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Yokomura K, Suda T (2019) Macrophage mannose receptor CD206 predicts prognosis in community-acquired pneumonia. Sci Rep 9(1):18750. https://doi.org/10.1038/s41598-019-55289-2 Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R (2017) Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science 356(6337):513–519. https://doi.org/10.1126/science.aal3535 Wehrhan F, Moebius P, Amann K, Ries J, Preidl R, Neukam FW, Weber M (2017) Macrophage and osteoclast polarization in bisphosphonate associated necrosis and osteoradionecrosis. J Craniomaxillofac Surg 45(6):944–953. https://doi.org/10.1016/j.jcms.2017.02.023 Hoefert S, Schmitz I, Weichert F, Gaspar M, Eufinger H (2015) Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases. Clin Oral Investig 19(2):497–508. https://doi.org/10.1007/s00784-014-1273-7 Russmueller G, Seemann R, Weiss K, Stadler V, Speiss M, Perisanidis C, Fuereder T, Willinger B, Sulzbacher I, Steininger C (2016) The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep 6:31604. https://doi.org/10.1038/srep31604 Ruggiero SL, Kohn N (2015) Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 73(12 Suppl):S94–S100. https://doi.org/10.1016/j.joms.2015.09.024 Aljohani S, Gaudin R, Weiser J, Troltzsch M, Ehrenfeld M, Kaeppler G, Smeets R, Otto S (2018) Osteonecrosis of the jaw in patients treated with denosumab: a multicenter case series. J Craniomaxillofac Surg 46(9):1515–1525. https://doi.org/10.1016/j.jcms.2018.05.046 Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513–523. https://doi.org/10.1016/S2213-8587(17)30138-9 Biswas SK, Mantovani A (2012) Orchestration of metabolism by macrophages. Cell Metab 15(4):432–437. https://doi.org/10.1016/j.cmet.2011.11.013 Mantovani A, Locati M (2013) Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 33(7):1478–1483. https://doi.org/10.1161/ATVBAHA.113.300168 Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K (2010) Development of monocytes, macrophages, and dendritic cells. Science 327(5966):656–661. https://doi.org/10.1126/science.1178331 Wang N, Liang H, Zen K (2014) Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol 5:614. https://doi.org/10.3389/fimmu.2014.00614 Evans KE, Fox SW (2007) Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol 8:4. https://doi.org/10.1186/1471-2121-8-4 Kaneko J, Okinaga T, Hikiji H, Ariyoshi W, Yoshiga D, Habu M, Tominaga K, Nishihara T (2018) Zoledronic acid exacerbates inflammation through M1 macrophage polarization. Inflamm Regen 38:16. https://doi.org/10.1186/s41232-018-0074-9 Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, Le AD (2013) IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin Cancer Res 19(12):3176–3188. https://doi.org/10.1158/1078-0432.CCR-13-0042 Morita M, Iwasaki R, Sato Y, Kobayashi T, Watanabe R, Oike T, Nakamura S, Keneko Y, Miyamoto K, Ishihara K, Iwakura Y, Ishii K, Matsumoto M, Nakamura M, Kawana H, Nakagawa T, Miyamoto T (2017) Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis. Sci Rep 7:46322. https://doi.org/10.1038/srep46322 Garbers C, Heink S, Korn T, Rose-John S (2018) Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17(6):395–412. https://doi.org/10.1038/nrd.2018.45 Kang S, Tanaka T, Narazaki M, Kishimoto T (2019) Targeting interleukin-6 signaling in clinic. Immunity 50(4):1007–1023. https://doi.org/10.1016/j.immuni.2019.03.026 Galli SJ, Borregaard N, Wynn TA (2011) Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 12(11):1035–1044. https://doi.org/10.1038/ni.2109 Yao Q, Liu J, Zhang Z, Li F, Zhang C, Lai B, Xiao L, Wang N (2018) Peroxisome proliferator-activated receptor gamma (PPARgamma) induces the gene expression of integrin alphaVbeta5 to promote macrophage M2 polarization. J Biol Chem 293(43):16572–16582. https://doi.org/10.1074/jbc.RA118.003161 Wasnik S, Rundle CH, Baylink DJ, Yazdi MS, Carreon EE, Xu Y, Qin X, Lau KW, Tang X (2018) 1,25-Dihydroxyvitamin D suppresses M1 macrophages and promotes M2 differentiation at bone injury sites. JCI Insight 3(17). https://doi.org/10.1172/jci.insight.98773 Zhang T, Shao B, Liu GA (2017) Rosuvastatin promotes the differentiation of peripheral blood monocytes into M2 macrophages in patients with atherosclerosis by activating PPAR-gamma. Eur Rev Med Pharmacol Sci 21(19):4464–4471 Zhu W, Xu R, Du J, Fu Y, Li S, Zhang P, Liu L, Jiang H (2019) Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J 33(4):5208–5219. https://doi.org/10.1096/fj.201801791RR